■目前尚不清楚中国内脏脂肪指数(cVAI)与非肥胖个体的代谢功能障碍相关的脂肪肝(MAFLD)和丙氨酸氨基转移酶(ALT)。在这项研究中,我们评估了cVAI预测非肥胖参与者MAFLD和ALT升高的能力.
■这项横断面研究从2019年3月至2022年1月招募了541名非肥胖受试者,年龄范围为18-80岁。肝脏脂肪变性通过超声诊断。根据cVAI四分位数将参与者分为四组。为了评估cVAI和MAFLD与ALT升高之间的关联,采用多因素logistic回归。产生受试者工作特征(ROC)曲线以评估cVAI预测MAFLD和升高的ALT的能力。
■与cVAI最低的组相比,cVAI最高的组与非肥胖MAFLD呈正相关[16.173(4.082-64.073),P<0.001]和升高的ALT[8.463(2.859-25.049),P<0.001]。cVAI的ROC曲线下面积(AUC)大于WC,腰围与身高比,或BMI用于预测男性的非肥胖MAFLD,女性,>38岁和≤38岁亚组(P<0.05),分别。此外,cVAI预测MAFLD的能力在女性中更好,年轻人,和受教育程度较高的个人(P<0.05)。cVAI对ALT水平升高也具有良好的预测能力[0.655(0.602-0.708)],尤其是女性,年轻人,受过高等教育的参与者。此外,cVAI与肝纤维化评分呈显著正相关(P<0.05),也是非肥胖MAFLD患者合并代谢综合征的重要指标[AUC=0.688(0.612~0.763)].
■cVAI与非肥胖MAFLD和ALT升高密切相关。cVAI可能是非肥胖MAFLD和ALT升高的可靠且可获得的预测因子。
UNASSIGNED: It is unclear how the Chinese Visceral Adiposity Index (cVAI) relates to metabolic dysfunction-associated fatty liver disease (MAFLD) and alanine aminotransferase (ALT) in nonobese individuals. In this study, we evaluated the ability of the cVAI to predict MAFLD and elevated ALT in nonobese participants.
UNASSIGNED: This cross-sectional study recruited 541 nonobese subjects from March 2019 to January 2022 with the age range of 18-80 years. Hepatic steatosis was diagnosed by ultrasound. Participants were divided into four groups according to cVAI quartiles. To assess the associations between cVAI and MAFLD and elevated ALT, multivariate logistic regression was used. Receiver operating characteristic (ROC) curves were generated to evaluate the ability of the cVAI to predict MAFLD and elevated ALT.
UNASSIGNED: Compared to the group with the lowest cVAI, the group with the highest cVAI was positively associated with nonobese MAFLD [16.173 (4.082-64.073), P < 0.001] and elevated ALT [8.463 (2.859-25.049), P < 0.001]. The area under the ROC curve (AUC) of the cVAI was greater than that of WC, waist-to-height ratio, or BMI for predicting nonobese MAFLD in the male, female, > 38 and ≤ 38 years old subgroups (P < 0.05), respectively. In addition, the ability of the cVAI to predict MAFLD was better in females, young individuals, and individuals with a higher education level (P < 0.05). The cVAI also had good predictive ability for elevated ALT levels [0.655 (0.602-0.708)], particularly in females, young people, and highly educated participants. Furthermore, the cVAI was strongly positively correlated with the liver fibrosis score (P < 0.05) and was also a strong indicator of concomitant metabolic syndrome in nonobese MAFLD patients [AUC = 0.688 (0.612-0.763)].
UNASSIGNED: The cVAI was strongly related to nonobese MAFLD and elevated ALT. The cVAI may be a reliable and accessible predictor of nonobese MAFLD and elevated ALT.